Core Insights - LifeVantage Corporation reported a strong financial performance for the fourth quarter and full fiscal year 2025, with a revenue growth of approximately 13% to $55.1 million in Q4 and 14.2% to $228.5 million for the full year [6][9][14] - The international business showed growth for the first time in nearly three years, particularly in the Asia/Pacific and Europe regions, which increased by approximately 8% [6][9] - The company has a strong balance sheet with $20.2 million in cash and no debt, positioning it well for future growth [22] Fourth Quarter Fiscal 2025 Summary - Revenue for Q4 was $55.1 million, a 12.6% increase year-over-year, with a 14.1% increase in the Americas and a 7.6% increase in Asia/Pacific & Europe [7][9] - Gross profit was $44.0 million, representing 79.9% of revenue, compared to 79.5% in Q4 fiscal 2024 [8] - Net income for Q4 was $2.0 million, or $0.15 per diluted share, up from $1.3 million, or $0.10 per diluted share in the prior year [12][9] Fiscal Year 2025 Summary - Total revenue for fiscal 2025 was $228.5 million, a 14.2% increase from $200.2 million in fiscal 2024 [14] - Gross profit for the year was $183.7 million, or 80.4% of revenue, compared to 79.3% in fiscal 2024 [15] - Net income for the year was $9.8 million, or $0.75 per diluted share, compared to $2.9 million, or $0.23 per diluted share in fiscal 2024 [19] Share Repurchase and Dividend - The company repurchased 0.3 million shares for $3.1 million during fiscal 2025, with approximately $17.3 million remaining under the current repurchase program [21] - A cash dividend of $0.045 per common share was declared, to be paid on September 16, 2025 [23] Fiscal Year 2026 Guidance - LifeVantage expects revenue in the range of $225 million to $240 million for fiscal 2026, with adjusted EBITDA of $23 million to $26 million [24]

Core Insights - LifeVantage Corporation announced new results from its second human clinical study on the MindBody GLP-1 System™, showing significant improvements in GLP-1 levels and related health outcomes [1][2] Clinical Study Results - The average increase in GLP-1 production improved to over 200%, up from a previously reported 140% [2] - Participants experienced an average weight loss of 11 pounds within 12 weeks, with some losing up to 25 pounds [6] - There was a reported decrease in total body fat percentage of up to 9% and a decrease in visceral fat of up to 24% [6] - Participants reported a 100% weight loss from fat, not muscle, and a 6% increase in skeletal muscle [6] Behavioral Changes - 95% of participants reported decreased sugar cravings, while 89% reported decreased fast-food cravings [6] - 85% of participants indicated they now eat for health instead of emotions, and 81% reported an increased ability to resist snacking [6] - 89% of participants ate less at meals, and 86% reported feeling less hungry [6] Company Background - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [5] - The company offers a range of products, including the MindBody GLP-1 System™, aimed at promoting optimal health at the cellular level [5]

Core Viewpoint - LifeVantage Corporation reported strong financial results for the third fiscal quarter of 2025, with a significant increase in revenue and profitability, driven by robust demand for its products and international expansion efforts [4][5]. Financial Performance - Revenue for the third quarter ended March 31, 2025, was $58.4 million, representing a 21.1% increase year-over-year. Excluding foreign currency fluctuations, revenue increased by 22.1% [5][9]. - Gross profit for the quarter was $47.3 million, or 81.0% of revenue, compared to 78.9% in the same period of fiscal 2024, attributed to a favorable product sales mix and reduced inventory costs [6]. - Adjusted EBITDA rose by 27% to $6.4 million from $5.1 million a year ago [9][12]. - Net income for the quarter was $3.5 million, or $0.26 per diluted share, compared to $1.7 million, or $0.13 per diluted share, in the prior year [11][9]. Regional Performance - Revenue in the Americas increased by 29.5%, with a notable 31.4% rise in the United States. Conversely, revenue in the Asia/Pacific & Europe region decreased by 7.2%, with a constant currency decline of approximately 4.7% [5][9]. Operational Highlights - The company launched its Evolve Compensation Plan in several Asian markets and introduced the MindBody GLP-1 System™ in multiple international regions, indicating a strategic focus on global market expansion [4]. - Active Independent Consultants increased by 6.1% to 52,000, with a 12.9% rise in the Americas, while the Asia/Pacific & Europe region saw a decline of 5.6% [32]. Balance Sheet and Liquidity - Cash and cash equivalents as of March 31, 2025, were $22.5 million, up from $16.9 million at the end of June 2024, with no debt outstanding [13]. - The company generated $10.8 million in cash from operations during the first nine months of fiscal 2025, compared to $9.6 million in the same period of fiscal 2024 [13]. Shareholder Returns - LifeVantage declared a cash dividend of $0.045 per common share, scheduled for payment on June 13, 2025 [15]. Fiscal Year Guidance - The company expects revenue for fiscal year 2025 to be in the range of $228 million to $235 million, with adjusted EBITDA guidance of $21 million to $24 million and adjusted earnings per share between $0.72 and $0.88 [16].